EHS
EHS

LXB improves functional outcomes in patients with idiopathic hypersomnia



LXB improved all measures of function and work productivity among patients with idiopathic hypersomnia, according to findings presented at the American Neurological Association Annual Meeting.
The treatment (calcium, magnesium, potassium and sodium oxybates; Jazz Pharmaceuticals Inc.), also referred to as lower-sodium oxybate (LXB) and Xywav, has the same active moiety at the same concentration as sodium oxybate but features 92% less sodium. The FDA approved LXB in August for adults with idiopathic hypersomnia.
“In a [prior] double-blind, placebo-controlled randomized withdrawal study in

Source link

EHS
Back to top button